Following the trace of elusive amines.

T classical biogenic amines (serotonin, noradrenaline, dopamine, and histamine) play important roles as neuromodulators. These transmitters are synthesized from precursor amino acids in specific neurons and stored in vesicles at synaptic terminals for release into the synaptic cleft in response to neuronal depolarization. In the extracellular space, the released amines bind to specific receptor proteins—primarily of the G protein-coupled receptor family—on both presynaptic and postsynaptic cells, where they modulate intracellular second messenger pathways to alter the signaling of the fast neurotransmitter-gated ion channels. After release, amines are taken back rapidly into the presynaptic neurons through specific transporters for repackaging into vesicles and re-release or are degraded to inactive products. The neurochemistry of biogenic amines is relatively well understood, including the control of amine synthesis from precursor amino acids, their storage and release, and their reuptake versus degradation. Imbalances in the levels of these amine neuromodulators are thought to underlie altered brain function in many pathological conditions, including dystonias, Parkinson’s disease, schizophrenia, drug addiction, and mood disorders. This obvious involvement of biogenic amines in multiple brain disorders has led to many years of effort to understand their action and to therapeutic interventions to correct deficits, either through activating or inhibiting the synthesis, storage, signaling, or metabolism of individual amines. For several decades, however, neurochemists and pharmacologists have appreciated that in addition to the major amine neuromodulators a series of less well characterized amines derived from the metabolism of amino acids are also present in many tissues in the body, but especially in the brain (1–4). A recent study published by Borowsky et al. in PNAS (5) is certain to rekindle the interest in this class of compounds. These amines include tyramine, tryptamine, octopamine, and b-phenylethylamine (1). In invertebrates, which lack the noradrenaline system, octopamine appears to serve as a major neurotransmitteryneuromodulator (6). In mammals, however, these so-called trace amines are present at generally low levels and there do not appear to be dedicated synapses using exclusively any of the trace amines (1–4, 6). Nevertheless, levels of these amines are altered in various disorders (Table 1), and blockade of amine degradation leads to significant accumulations of trace amines indicative of a high level of synthesis and turnover, suggesting that these trace amines may play important roles. One of the roles suggested for these compounds is as ‘‘false transmitters,’’ which displace biologically active biogenic amines from their storage and act on transporters much like the amphetamines (7). However, these compounds are not thought of as active neuromodulators. Results from the study (5) suggest that the trace amines may be much more than metabolic curiosities or aminergic wannabe’s, but may function as distinct and bona fide neuromodulators. Using degenerate amplification, bioinformatics and comparative genomics, Borowsky and coworkers have identified 15 members of two distinct families of G protein-coupled receptors with a high degree of similarity to traditional G protein-coupled biogenic amine receptors. They demonstrate that one of these receptors, called TA1, is a receptor for two of the trace amines, b-phenylethylamine and tyramine. TA1 binds to both b-phenylethylamine and tyramine with high affinity and produces cAMP in response to this binding, whereas the related TA2 receptor appears to be specific for b-phenylethylamine and tryptamine. Both of these G protein-coupled receptor families possess many of the structural hallmarks of the rhodopsinyb-adrenergic receptor superfamily (8). Among these are several highly conserved stretches of residues in the predicted transmembrane (TM) regions, such as the (EyD) R (YyH) motif at the end of the third TM domain and the NPXXY motif in the seventh TM, as well as potential sites of regulatory phosphorylation in the C-terminal domain. Thus, these receptors are likely to couple to conventional signaling pathways as demonstrated for TA1 (5) and their signaling is likely to be regulated through mechanisms similar to those for other G protein-coupled receptors (8). Several of these new receptors are expressed within specific regions of the central nervous system, whereas others appear to be found in specific peripheral tissues such as stomach, kidney, lung, and small intestine. In the central nervous system, the mRNA for the TA1 and TA2 receptor proteins can be found sparsely expressed in certain cells of the substantia nigrayventral tegmental area, locus coeruleus, and dorsal raphe nucleus, areas where the cell bodies for the classic biogenic amines neurons are found (5). That G protein-coupled receptors exist in the brain that respond specifically to trace amines such as b-phenylethylamine and tyramine satisfies one additional criterion for classifying these molecules as neurotransmittersyneuromodulators. Although there appear to be no neurons using any of the trace amines exclusively, these molecules can be packaged and released along with traditional amines (1–4, 7), and so may function as traditional neuromodulators working through their own receptors. In addition, because these trace amines are primarily generated through decarboxylation of their respective amino acid precursors via aromatic amino acid decarboxylase (1–4), which is involved in the synthesis of the major monoamine neurotransmitters, a spatially restricted mechanism for their synthesis exists. Levels of trace amines also seem to be dynamically regulated, because inhibition of monoamine oxidase leads to